Cat. No.: HY-10202

Tandutinib

(Synonyms: MLN518; CT53518)

5 Cited Publications

Avis client

Based on 5 publication(s) in Google Scholar

Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML). Tandutinib has the ability to cross the blood-brain barrier.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.48%
CAS No.: 387867-13-2
Formule: C₃₁H₄₂N₆O₄
Masse moléculaire:562.70

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Tandutinib Chemical Structure

CAS No.: 387867-13-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (5)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML)^[1]^[2]. Tandutinib has the ability to cross the blood-brain barrier^[3].

IC₅₀ & Target^[1]

PDGFR

0.2 μM (IC₅₀)

FLT3

0.22 μM (IC₅₀)

c-Kit

0.17 μM (IC₅₀)

Voir tous les produits spécifiques à Isoform PDGFR :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	>10000 nM Compound: MLN-518	Toxicity against human A375 cells after 72 hrs by cell titer-blue assay Toxicity against human A375 cells after 72 hrs by cell titer-blue assay	[PMID: 19654408]
A549	IC₅₀	14.75 μM Compound: Tandutinib	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 27575478]
BaF3	IC₅₀	10 nM Compound: Tandutinib	Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD mutant assessed as inhibition of cell proliferation measured after 72 hrs by celltiter-glo luminescent cell viability assay Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD mutant assessed as inhibition of cell proliferation measured after 72 hrs by celltiter-glo luminescent cell viability assay	[PMID: 32659083]
CHO	IC₅₀	0.17 μM Compound: 75	Inhibition of chimeric PDGF receptor with c-kit cytoplasmic domain phosphorylation in CHO cells Inhibition of chimeric PDGF receptor with c-kit cytoplasmic domain phosphorylation in CHO cells	[PMID: 12166950]
CHO	IC₅₀	0.2 μM Compound: 75	Inhibition of wild type Platelet-derived growth factor receptor beta phosphorylation in CHO cells Inhibition of wild type Platelet-derived growth factor receptor beta phosphorylation in CHO cells	[PMID: 12166950]
CHO	IC₅₀	0.22 μM Compound: 75	Inhibition of chimeric PDGF receptor with FLT-3 cytoplasmic domain phosphorylation in CHO cells Inhibition of chimeric PDGF receptor with FLT-3 cytoplasmic domain phosphorylation in CHO cells	[PMID: 12166950]
CHO	IC₅₀	3.43 μM Compound: 75	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	[PMID: 12166950]
HCT-116	IC₅₀	18.13 μM Compound: Tandutinib	Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 27575478]
HL-60	GI₅₀	>10 μM Compound: MLN518	Growth inhibition of human HL60 cells after 48 hrs by XTT assay Growth inhibition of human HL60 cells after 48 hrs by XTT assay	[PMID: 25108079]
K562	GI₅₀	>10 μM Compound: MLN518	Growth inhibition of human K562 cells after 48 hrs by XTT assay Growth inhibition of human K562 cells after 48 hrs by XTT assay	[PMID: 25108079]
K562	IC₅₀	>10000 nM Compound: MLN-518	Antiproliferative activity against FLT3-deficient human K562 cells after 72 hrs by MTT assay Antiproliferative activity against FLT3-deficient human K562 cells after 72 hrs by MTT assay	[PMID: 27266526]
K562	IC₅₀	9.21 μM Compound: MLN518	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31614258]
Kasumi 1	IC₅₀	0.022 μM Compound: MLN-518	Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay	[PMID: 20570526]
Leukemia cell	IC₅₀	0.29 μM Compound: 2	Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-ITD mutation assessed as cell viability after 72 hrs by luciferase assay Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-ITD mutation assessed as cell viability after 72 hrs by luciferase assay	[PMID: 22221201]
Leukemia cell	IC₅₀	0.64 μM Compound: 2	Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing wild type FLT3 assessed as cell viability after 72 hrs by luciferase assay Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing wild type FLT3 assessed as cell viability after 72 hrs by luciferase assay	[PMID: 22221201]
Leukemia cell	IC₅₀	3.4 μM Compound: 2	Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-D835Y mutation assessed as cell viability after 72 hrs by luciferase assay Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-D835Y mutation assessed as cell viability after 72 hrs by luciferase assay	[PMID: 22221201]
MCF7	IC₅₀	14.7 μM Compound: Tandutinib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 27575478]
MG-63	IC₅₀	0.026 μM Compound: 75	Inhibition of platelet-derived growth factor receptor beta phosphorylation in MG63 cells in the absence of plasma Inhibition of platelet-derived growth factor receptor beta phosphorylation in MG63 cells in the absence of plasma	[PMID: 12166950]
MG-63	IC₅₀	0.036 μM Compound: 75	Inhibition of platelet derived growth factor receptor beta phosphorylation in MG63 cells in the presence of human plasma Inhibition of platelet derived growth factor receptor beta phosphorylation in MG63 cells in the presence of human plasma	[PMID: 12166950]
MOLM-13	IC₅₀	0.081 μM Compound: MLN-518	Antiproliferative activity against human MOLM13 cells after 72 hrs by MTT assay Antiproliferative activity against human MOLM13 cells after 72 hrs by MTT assay	[PMID: 20570526]
MOLM-13	IC₅₀	10 nM Compound: Tandutinib	Antiproliferative activity against human MOLM-13 cells expressing FLT3-ITD mutant assessed as inhibition of cell proliferation measured after 72 hrs by celltiter-glo luminescent cell viability assay Antiproliferative activity against human MOLM-13 cells expressing FLT3-ITD mutant assessed as inhibition of cell proliferation measured after 72 hrs by celltiter-glo luminescent cell viability assay	[PMID: 32659083]
MOLM-13	GI₅₀	0.052 μM Compound: MLN518	Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 32975953]
MOLM-13	GI₅₀	1.9 μM Compound: MLN518	Antiproliferative activity against human MOLM-13 cells harboring D835Y mutant assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human MOLM-13 cells harboring D835Y mutant assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 32975953]
MOLM-14	IC₅₀	10 nM Compound: Tandutinib	Antiproliferative activity against human MOLM-14 cells expressing FLT3-ITD mutant assessed as inhibition of cell proliferation measured after 72 hrs by celltiter-glo luminescent cell viability assay Antiproliferative activity against human MOLM-14 cells expressing FLT3-ITD mutant assessed as inhibition of cell proliferation measured after 72 hrs by celltiter-glo luminescent cell viability assay	[PMID: 32659083]
MV4-11	IC₅₀	60 nM Compound: MLN-518	Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay	[PMID: 19654408]
MV4-11	IC₅₀	0.119 μM Compound: MLN-518	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 20570526]
MV4-11	IC₅₀	0.055 μM Compound: MLN518	Cytotoxicity against FLT3-dependent human MV4-11 cells after 72 hrs by MTT assay Cytotoxicity against FLT3-dependent human MV4-11 cells after 72 hrs by MTT assay	[PMID: 22452518]
MV4-11	GI₅₀	8.756 μM Compound: MLN518	Growth inhibition of human MV411 cells after 48 hrs by XTT assay Growth inhibition of human MV411 cells after 48 hrs by XTT assay	[PMID: 25108079]
MV4-11	IC₅₀	302 nM Compound: MLN-518	Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant after 72 hrs by MTT assay	[PMID: 27266526]
MV4-11	IC₅₀	0.06 μM Compound: MLN518	Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31614258]
P815	IC₅₀	600 nM Compound: 3	Cytotoxicity in mouse P815 cells expressing KIT D814Y mutant assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in mouse P815 cells expressing KIT D814Y mutant assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29678462]
RS4-11	IC₅₀	170 nM Compound: MLN-518	Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay	[PMID: 19654408]
RS4-11	IC₅₀	33 nM Compound: MLN-518	Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay	[PMID: 19654408]
RS4-11	IC₅₀	>5 μM Compound: MLN-518	Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay	[PMID: 20570526]
Sf9	IC₅₀	0.22 μM Compound: 19; MLN518, CT53518	Inhibition of N-terminal GST-tagged human FLT3 (563 to 993 residues) cytoplasmic domain expressed in baculovirus infected sf9 cells using EAIYAAPFAKKK as substrate after 10 mins in presence of [gamma-33P]-ATP by scintillation counting method Inhibition of N-terminal GST-tagged human FLT3 (563 to 993 residues) cytoplasmic domain expressed in baculovirus infected sf9 cells using EAIYAAPFAKKK as substrate after 10 mins in presence of [gamma-33P]-ATP by scintillation counting method	[PMID: 31207462]
THP-1	IC₅₀	1 μM Compound: MLN-518	Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay	[PMID: 20570526]
THP-1	GI₅₀	>10 μM Compound: MLN518	Growth inhibition of human THP1 cells after 48 hrs by XTT assay Growth inhibition of human THP1 cells after 48 hrs by XTT assay	[PMID: 25108079]
U-937	IC₅₀	>5 μM Compound: MLN-518	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	[PMID: 20570526]
U-937	IC₅₀	19.8 μM Compound: MLN518	Antiproliferative activity against human U937 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human U937 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31614258]
WI-38	IC₅₀	>10000 nM Compound: MLN-518	Antiproliferative activity against human WI38 cells after 72 hrs by SRB assay Antiproliferative activity against human WI38 cells after 72 hrs by SRB assay	[PMID: 27266526]

In Vitro

Tandutinib (0-3 μM; 30 minutes; Ba/F3 cells) treatment inhibits IL-3-independent cell growth and FLT3-ITD autophosphorylation with an IC₅₀ of 10-100 nM in Ba/F3 cells expressing different FLT3-ITD mutants^[1].
Tandutinib (1 μM; 24-96 hours; Molm-14 and THP-1 AML cells) treatment induces apoptosis in FLT3-ITD-positive AML cells^[1].
In human FLT3-ITD-positive AML cell lines, Tandutinib inhibits FLT3-ITD phosphorylation (IC₅₀ of ~30 nM). As with Erk2, a constitutively high level of Akt phosphorylation is readily detected and is efficiently blocked by pretreatment of the Molm-14 cells with 100-300 nM Tandutinib^[1].
Tandutinib inhibits cell proliferation of the FLT3-ITD-positive Molm-13 and Molm-14 with an IC₅₀ of 10 nM. And signaling through the MAP kinase and PI3 kinase pathways^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

Molm-14 and THP-1 AML cells
Concentration:

1 μM
Incubation Time:

24 hours, 48 hours, 72 hours, 96 hours
Result:

Induced apoptosis in FLT3-ITD-positive AML cells.

Western Blot Analysis^[1]

Cell Line:

Ba/F3 cells
Concentration:

0 μM, 0.003 μM, 0.01 μM, 0.03 μM, 0.1 μM, 1 μM and 3 μM
Incubation Time:

30 minutes
Result:

In Ba/F3 cells expressing different FLT3-ITD mutants, inhibited IL-3-independent cell growth and FLT3-ITD autophosphorylation.

In Vivo

Tandutinib (60 mg/kg; oral gavage; daily; for 35 days; athymic nude mice) treatment causes a statistically significant increase in survival that was extended on average by 20 days^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic nude mice injected with Ba/F3 cells^[1]
Dosage:

60 mg/kg
Administration:

Oral gavage; daily; for 35 days
Result:

Caused a statistically significant increase in survival that was extended on average by 20 days.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 387867-13-2
Appearance Solid
Masse moléculaire 562.70
Formule C₃₁H₄₂N₆O₄
Color White to light yellow
SMILES

O=C(N1CCN(C2=C(C(C=C3OCCCN4CCCCC4)=NC=N2)C=C3OC)CC1)NC5=CC=C(OC(C)C)C=C5
Synonyms

MLN518; CT53518
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All

Sort by:

Journal Impact Factor

Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Drug Des Devel Ther

LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay. [Abstract]

2020 Oct 23;14:4439-4449. PMID: 33122888
Drug Des Devel Ther

Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). [Abstract]

2018 Apr 30:12:1009-1017. PMID: 29750014
Cancers (Basel)

Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma. [Abstract]

2022 Nov 28;14(23):5854. PMID: 36497337
Biochem Biophys Res Commun

The angiogenic factor Egfl7 alters thymogenesis by activating Flt3 signaling. [Abstract]

2017 Aug 19;490(2):209-216. PMID: 28601636

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (88.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7771 mL

8.8857 mL

17.7715 mL

5 mM

0.3554 mL

1.7771 mL

3.5543 mL

10 mM

0.1777 mL

0.8886 mL

1.7771 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kelly LM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 2002, 1(5), 421-432. [Content Brief]

[2]. Griswold IJ, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 2004, 104(9), 2912-2918. [Content Brief]

[3]. Yang JJ, et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett. 2010 Dec;4(4):201-12. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7771 mL	8.8857 mL	17.7715 mL	44.4286 mL
	5 mM	0.3554 mL	1.7771 mL	3.5543 mL	8.8857 mL
	10 mM	0.1777 mL	0.8886 mL	1.7771 mL	4.4429 mL
	15 mM	0.1185 mL	0.5924 mL	1.1848 mL	2.9619 mL
	20 mM	0.0889 mL	0.4443 mL	0.8886 mL	2.2214 mL
	25 mM	0.0711 mL	0.3554 mL	0.7109 mL	1.7771 mL
	30 mM	0.0592 mL	0.2962 mL	0.5924 mL	1.4810 mL
	40 mM	0.0444 mL	0.2221 mL	0.4443 mL	1.1107 mL
	50 mM	0.0355 mL	0.1777 mL	0.3554 mL	0.8886 mL
	60 mM	0.0296 mL	0.1481 mL	0.2962 mL	0.7405 mL
	80 mM	0.0222 mL	0.1111 mL	0.2221 mL	0.5554 mL

Tandutinib

5 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Tandutinib

Apoptosis Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) Tandutinib

Voir tous les produits spécifiques à Isoform PDGFR

Activité biologique

Chemical Information

Publications (5)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Tandutinib Related Classifications

HY-10202 Related Classifications